SuperworthIntuitive Surgical ISRG
- Market cap
- $159.8B
- PE
- 54.7×
- 10y median 69.3×
- Forward PE
- 37.5×
- 10y median 52.8×
- Price to sales
- 13.8×
- EV/EBIT
- 47.5×
- Revenue, 12 months
- $11.6B
- +20% on a year ago
- Net margin
- 25.5%
- Free cash flow yield
- n/m
- Q3 FY26 missing
Intuitive Surgical trades at 54.7× trailing earnings, cheaper than 67% of the last ten years. Revenue was $11.6B over the last twelve months, up 20% on a year earlier with a 26% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.9B+17% | $1.9B+12% | $2B+15% | $2B+17% | $2.4B+25% | $2.3B+19% | $2.4B+21% | $2.5B+23% | $2.9B+19% | $2.8B+23% | $2.9B+19% | $3B+22% | |
| Cost of revenue | $650.9M+20% | $645.2M+11% | $637.2M+9% | $664.2M+15% | $771.3M+19% | $795.7M+23% | $822.1M+29% | $842.7M+27% | $961.9M+25% | $940.3M+18% | $931.9M+13% | $964.4M+14% |
| Gross profit | $1.3B+15% | $1.2B+12% | $1.4B+17% | $1.4B+18% | $1.6B+29% | $1.5B+17% | $1.6B+18% | $1.7B+21% | $1.9B+16% | $1.8B+26% | $2B+21% | n/a |
| R&D | $260.1M+7% | $284.5M+16% | $280.1M+15% | $286M+15% | $294.7M+13% | $316.2M+11% | $313.3M+12% | $329.4M+15% | $352.9M+20% | $361.9M+15% | $370.6M+18% | $408.3M+24% |
| SG&A | $567.1M+15% | $491.5M+2% | $525.3M+13% | $510.6M+13% | $612.6M+8% | $563.4M+15% | $561.2M+7% | $573.3M+12% | $687.1M+12% | $613.3M+9% | $617.9M+10% | $1.1B+89% |
| $450.2M+21% | $469.4M+21% | $567.3M+23% | $577.3M+24% | $734.9M+63% | $578.1M+23% | $743.4M+31% | $759.7M+32% | $864.3M+18% | $855.3M+48% | $971.9M+31% | $592.6M−22% | |
| Pre-tax income | $515.9M+31% | $538.5M+28% | $654.5M+31% | $671M+29% | $809.8M+57% | $668.5M+24% | $832.1M+27% | $855.2M+28% | $955.6M+18% | $940.4M+41% | $1.1B+27% | $668.4M−22% |
| −$94.8M | −$8.9M | $123M+68% | $100.4M−2% | $121.8M | −$35.2M+296% | $167.9M+37% | $146M+45% | $156.1M+28% | $114.4M | $231.4M+38% | $144M−1% | |
| Net income | $606.2M+87% | $544.9M+53% | $526.9M+25% | $565.1M+36% | $685.7M+13% | $698.4M+28% | $658.4M+25% | $704.4M+25% | $794.8M+16% | $821.5M+18% | $818.1M+24% | $522.8M−26% |
| $1.69+86% | $1.51+51% | $1.46+24% | $1.56+35% | $1.88+11% | $1.92+27% | $1.81+24% | $1.95+25% | $2.21+18% | $2.28+19% | $2.29+27% | $1.49−24% | |
| 358.2M+0% | 360.5M+1% | 361M+1% | 362.7M+1% | 363.9M+2% | 364.6M+1% | 364.1M+1% | 361.8M−0% | 360.4M−1% | 359.8M−1% | 357.3M−2% | 351.6M−3% |
Net income: 4 periods, Q4 FY22 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: Q4 FY08 and Q4 FY17: quarter's net income to common over its shares, to the cent. 5 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 12 periods, Q4 FY08 to Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 5 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $3.2B | $3.2B to $3.3B | $2.95 | $2.92 to $2.98 | 16 |
| Q1 FY27 | $3.1B | $3B to $3.2B | $2.85 | $2.80 to $2.91 | 13 |
| Q2 FY27 | $3.2B | $3.1B to $3.3B | $3.08 | $2.96 to $3.19 | 5 |
| Q3 FY27 | $3.4B | $3.3B to $3.5B | $3.18 | $3.05 to $3.29 | 5 |
| Q4 FY27 | $3.6B | $3.5B to $3.7B | $3.32 | $3.20 to $3.45 | 5 |
| Q1 FY28 | $3.4B | $3.3B to $3.5B | $3.05 | $2.93 to $3.16 | 6 |
| Q2 FY28 | $3.5B | $3.4B to $3.6B | $3.31 | $3.19 to $3.44 | 6 |
| Q3 FY28 | $3.6B | $3.5B to $3.7B | $3.39 | $3.26 to $3.52 | 6 |
Peers
Companies in Medical - Instruments & Supplies nearest Intuitive Surgical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ISRGIntuitive Surgical | $159.8B | 54.7× | 69.3× | 37.5× | 13.8× | +20% | 25.5% |
| BDXBecton, Dickinson and | $54.2B | 60.1× | 37.5× | 15.1× | 2.6× | +5% | 4.5% |
| MDLNMedline | $44.8B | n/m | n/a | 23.2× | n/m | n/m | n/m |
| RMDResMed | $36.5B | 24.2× | 37.3× | 20.8× | 6.5× | +10% | 26.9% |
| WSTWest Pharmaceutical Services | $27.6B | 50.2× | 45.8× | 42.2× | 8.3× | +12% | 17.0% |
| Peer median | $40.6B | 50.2× | 37.5× | 22.0× | 6.5× | +10% | 17.0% |
Investors who own it
Investors we follow who held Intuitive Surgical at the end of Jun 30, 2026, from their 13F filings.
- Polen CapitalPolen Capital1.5% of portfoliotrimmed
- Baillie GiffordBaillie Gifford0.9% of portfoliotrimmed
- Dan SundheimD1 Capital Partners0.7% of portfolionew
- Philippe LaffontCoatue Management0.6% of portfoliotrimmed
- Cathie WoodARK Investment Management0.2% of portfolioadded
- Ron BaronBaron Capital0.1% of portfoliotrimmed
More on Intuitive Surgical
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 80Medical instruments and supplies stocks with the highest profit margins
- #10of 23Medical instruments and supplies stocks cheapest against their own PE history
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .